3 Mar 2021 12:10
Evgen Pharma plc
("Evgen" or "the Company")
Result of General Meeting
and
Total Voting Rights
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces that at the General Meeting held earlier today, the Resolutions proposed were duly passed by shareholders on a poll.
The numbers of votes cast for and against each of the Resolutions are detailed below:
Resolution | Votes for | % of votes cast | Votes against | % of votes cast | Total votes cast | Votes withheld |
1 | 34,363,025 | 99.91% | 30,000 | 0.09% | 34,393,025 | 108,375 |
2 | 34,324,025 | 99.82% | 61,695 | 0.18% | 34,385,720 | 115,680 |
It is expected that the Admission of the Placing Shares and the Open Offer shares will become effective at 8:00 a.m. on 4 March 2021.
Following Admission, the Company will have in issue 274,888,117 Ordinary Shares, with no shares held in treasury. Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.
Unless otherwise defined, terms in this announcement shall have the same meanings as those defined in the Placing and Open Offer announcement issued on 2 February 2021.
Enquiries:
Evgen Pharma plc www.evgen.com | via Walbrook |
Dr Huw Jones CEO | |
Richard Moulson, CFO | |
finnCap www.finncap.com | +44 (0) 20 7220 0500 |
Geoff Nash / Teddy Whiley (Corporate Finance) | |
Alice Lane, Manasa Patil (ECM) | |
Walbrook PR | +44 (0)20 7933 87870 or evgen@walbrookpr.com |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 |
About Evgen Pharma plc
Evgen Pharma is a clinical stage company developing sulforaphane based medicines for the treatment of multiple diseases The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. Our lead product, SFX-01, has demonstrated efficacy in a Phase II trial for advanced metastatic breast cancer. It has been used to treat over 150 patients in clinical trials and is well-tolerated with predominately mild side-effects.
Evgen shares are traded on the AIM market of the London Stock under the ticker symbol EVG.
For further information, please visit: www.evgen.com
Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):
1. | Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA') | |||||
a) | Name | Huw Jones | ||||
2. | Reason for notification | |||||
b) | Position / status | CEO | ||||
c) | Initial notification / amendment | Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
b) | Name | Evgen Pharma plc | ||||
c) | LEI | 213800NO3E6TSTQO8K20 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code
| ordinary shares of 0.25p each
GB00BSVYN304 | ||||
b) | Nature of the transaction | Acquisition of shares pursuant to the Placing | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | As above | ||||
e) | Date of the transaction | 3 March 2021 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
1. | Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA') | |||||
a) | Name | Sue Foden | ||||
2. | Reason for notification | |||||
b) | Position / status | Non-Executive Director | ||||
c) | Initial notification / amendment | Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
b) | Name | Evgen Pharma plc | ||||
c) | LEI | 213800NO3E6TSTQO8K20 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code
| Ordinary Shares of 0.25p each
GB00BSVYN304 | ||||
b) | Nature of the transaction | Acquisition of shares pursuant to the Placing | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price | As above | ||||
e) | Date of the transaction | 3 March 2021 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||